Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161441 | 1.00 | DPP4 (0.42) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL12140543 | 1.00 | DPP4 (0.42) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL29609345 | 0.99 | DPP4 (0.41) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL24690585 | 0.94 | DPP4 (0.35) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL30001751 | 0.92 | CTSV (0.35) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL24486588 | 0.87 | DPP4 (0.39) | DPP4DPP7DPP8DPP9FAP | |
| SCHEMBL10138782 | 0.86 | ALDH1A1 (0.34) | — | |
| SCHEMBL12605020 | 0.86 | ALDH1A1 (0.34) | — | |
| SCHEMBL31374981 | 0.86 | DPP4 (0.41) | DPP4DPP7DPP8DPP9FAP | |
| Hydrochloric Acid SCHEMBL31376809 | 0.85 | DPP4 (0.40) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022111-A1 | CELL-PERMEANT COVALENT INHIBITORS OF VIRAL CYSTEINE PROTEASES | UNIV LELAND STANFORD JUNIOR (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4166539-A1 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | DPP4 136/4885DPP7 550/4885DPP8 1653/4885 |
| US-20220142976-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | DPP4 136/4885DPP7 550/4885DPP8 1653/4885 |
| US-20260022111-A1 | CELL-PERMEANT COVALENT INHIBITORS OF VIRAL CYSTEINE PROTEASES | ACE2, ACE, TMPRSS2 | DPP4 32/4885DPP7 19/4885DPP8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.